Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Maya Gurnani"'
Autor:
Maya Gurnani, Nicholas Bauman, Cara A. Mendrick, R. Jason Herr, Paul M. McNicholas, Nathaniel Brown, Barry Antonacci, Anthony Cacciapuoti, Samuel Wainhaus, Andrew S. Chau, Michelle F. Waldman, Todd A. Black, Paul Mann, Christine Norris, Rongze Kuang, Ilias Triantafyllou, Pauline C. Ting, Yiming Xu, Robert G. Aslanian, Scott S. Walker, Reena Patel
Publikováno v:
Antimicrobial Agents and Chemotherapy. 55:5099-5106
The echinocandins are a class of semisynthetic natural products that target β-1,3-glucan synthase (GS). Their proven clinical efficacy combined with minimal safety issues has made the echinocandins an important asset in the management of fungal infe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed1f9234d0d4fb0c4579feb6e0de3fae
https://doi.org/10.1128/aac.00432-11
https://doi.org/10.1128/aac.00432-11
Autor:
Armin Wolf, Francois Pognan, Nandita Shangari, Lee Anne McLean, Elba Cruz, Parul Patel, Salah-Dine Chibout, Shruthi Sampath, Pierre Moulin, Steve Busch, Chiara Buono, Albert Reising, Maya Gurnani
Publikováno v:
Toxicological Sciences
Toxicological Sciences; Vol 126
Toxicological Sciences; Vol 126
Lens explant cultures were used to assess the mechanism of drug-induced cataractogenic potential of NVS001, a peroxisome proliferator-activated receptor delta (PPARδ) agonist, which resulted in cataract in all treated animals during a 13-week rat st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73a2a496909310b2e3e368b2ee6b548c
Autor:
Anthony Cacciapuoti, Paul M. McNicholas, Michel Laverdière, Andrew S. Chau, Maya Gurnani, Robyn Hawkinson
Publikováno v:
Antimicrobial Agents and Chemotherapy. 49:3646-3651
Two clinical Candida albicans isolates that exhibited high-level resistance to azoles and modest decreases in susceptibility to amphotericin B were cultured from unrelated patients. Both isolates harbored homozygous nonsense mutations in ERG3 , which
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::982358ea5aa65d62c0ef6c4bd28953e3
https://doi.org/10.1128/aac.49.9.3646-3651.2005
https://doi.org/10.1128/aac.49.9.3646-3651.2005
Autor:
Loretta L. Nielsen, Lei Xie, Ruth DiGiacomo, Maya Gurnani, Suxing Liu, Matthew McDonald, Stephen R. Indelicato, Bin Shi, Shu Fen Wen, Alice Chang, Beth Hutchins
Publikováno v:
Cancer Gene Therapy. 7:1469-1480
SCH58500 (ACN53) is a replication-deficient, type 5 adenovirus (Ad) expressing human wild-type p53 tumor suppressor. It is currently undergoing clinical trials as a cancer therapeutic. Many SCH58500 clinical trials incorporate an arm comparing tradit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8496b3f4ba1163ed5aad7dc9a481627d
https://doi.org/10.1038/sj.cgt.7700257
https://doi.org/10.1038/sj.cgt.7700257
Autor:
Shijun Cui, Grace Michael, Alice Chang, Loretta L. Nielsen, Stephen R. Indelicato, Mary Lynn Musco, Lei Xie, Maya Gurnani, Robert C. Johnson, Jameel Syed, Ruth DiGiacomo
Publikováno v:
The American Journal of Pathology. 155:1869-1878
SCH58500 is an agent for gene therapy of cancer, consisting of a replication-deficient type 5 adenovirus (Ad5) expressing the human p53 tumor suppressor gene (Ad5/p53). An important question about the use of Ad5/p53 gene therapy is how to achieve the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d5cf07dda7b40515d752ef08fb6ba206
https://doi.org/10.1016/s0002-9440(10)65506-x
https://doi.org/10.1016/s0002-9440(10)65506-x
Publikováno v:
Cancer Chemotherapy and Pharmacology. 44:143-151
Purpose: Adenovirus-mediated p53 gene therapy for cancer is currently undergoing phase I/II clinical trials. The drug used in our clinical trials (p53 Ad; ACN53; SCH58500) consists of a replication-deficient, type 5 adenovirus vector expressing human
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d19aa9f909fa97cafb465fa4ae515e4a
https://doi.org/10.1007/s002800050959
https://doi.org/10.1007/s002800050959
Autor:
Reena Patel, Anthony Cacciapuoti, Christine Norris, David Loebenberg, Judith Halpern, Maya Gurnani
Publikováno v:
Antimicrobial agents and chemotherapy. 49(2)
The interaction of posaconazole and amphotericin B was evaluated in concomitant treatment of Candida albicans systemic infections in immunocompetent mice by using four strains of C. albicans with different susceptibilities to fluconazole. Posaconazol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df59dcec937cf91aae3f9e4b6eaec78b
https://pubmed.ncbi.nlm.nih.gov/15673745
https://pubmed.ncbi.nlm.nih.gov/15673745
Autor:
Rosie Bocanegra, F. Menzel, John R. Graybill, Laura K. Najvar, Steve Hernandez, Maya Gurnani, Anthony Cacciapuoti, David Loebenberg, Judith Halpern
Publikováno v:
Antimicrobial agents and chemotherapy. 48(3)
Posaconazole and/or amphotericin B was given to mice pretreated with a steroid and then infected by inhalation of Aspergillus flavus conidia. Two laboratories conducted studies using almost identical protocols to evaluate both survival and lung tissu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fcfaa515c358b1d1e1c9be88a582d05b
https://pubmed.ncbi.nlm.nih.gov/15273155
https://pubmed.ncbi.nlm.nih.gov/15273155
Autor:
Robert C. Johnson, Loretta L. Nielsen, Janet Dell, Barbara Hartman, Mark E. Cartwright, Jameel Syed, Maya Gurnani
Publikováno v:
Human gene therapy. 9(5)
Type 5 adenoviral (Ad) vectors have been the "vector-of-choice" for preclinical studies on p53 tumor suppressor gene therapy of cancer. Previous studies have examined the in vivo efficacy of p53 Ad when given intratumorally. However published informa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7aaa96b1139b0b2a86af4bc13a696a0d
https://pubmed.ncbi.nlm.nih.gov/9551616
https://pubmed.ncbi.nlm.nih.gov/9551616